Navigation Links
Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction
Date:1/25/2012

biological mechanism of action that the outcomes of the current study are intended to demonstrate.  The Amorcyte therapy is being developed initially for the preservation of heart muscle function for approximately 160,000 American patients who sustain a heart muscle damaging STEMI annually.

Dr. Pecora further added, "Even with current best clinical practices, this group faces a significant chance of adverse outcomes, including premature death.  Our goal is to create significant pharmacoeconomic value by reducing the associated costs of adverse outcomes often seen in these patients. We feel AMR-001 has the potential to address a substantial unmet medical need."

For more information on the clinical trial please visit www.amorcyte.com or view the NeoStem corporate presentation at www.neostem.com/investor-relations/.

About NeoStem, Inc. and Amorcyte, LLC, a NeoStem companyNeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, LLC, also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR 001, represents NeoStem's most clinically advanced therapeutic and is open for enrollment in a Phase 2 trial for the preservation of heart muscle function after a heart attack.  Amorcyte expects to begin a Phase 1 clinical trial in 2012 for AMR-001 for
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
2. NeoStem Provides Updates, Reports Results for Third Quarter and Upcoming November Company Presentations
3. NeoStem Announces Change in Presentation Time for JMP Securities Conference
4. NeoStem Announces Participation in Multiple September Conferences
5. NeoStem Appoints Grant Thornton LLP as New Independent Registered Public Accounting Firm
6. NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter
7. NeoStem Announces Pricing of Public Offering for $16,500,000 in Gross Proceeds
8. NeoStem Announces Proposed Public Offering of Common Stock
9. NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction
10. NeoStem Announces Agreement with Nankai Hospital in Tianjin to Offer NeoStems Licensed Orthopedic Technology
11. NeoStems Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 ... the addition of the "Market Assessment of ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... the respiratory imaging diagnostics market in ... Europe . The service provides detailed analysis ...
(Date:5/21/2015)... , May 21, 2015  CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today ... cash dividend for the second quarter 2015 of $0.03 ... dividend of $0.03 per share will be paid on ... as of June 12, 2015.  The ex-dividend date for ...
(Date:5/21/2015)... 21, 2015  (MUSE Booth # 1510)What:Automating continuous ... (EHR) is invaluable in any hospital setting, but ... a requirement and mainstream in healthcare, the integration ... EHR is gaining traction in MEDITECH facilities.During MUSE ... Site Project Manager & Clinical Analyst at McLaren ...
Breaking Medicine Technology:United States and Europe Respiratory Diagnostics Market Assessment 2015 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Hospital Streamlines ICU Efficiency with Timely Data Integration 2Hospital Streamlines ICU Efficiency with Timely Data Integration 3
(Date:5/22/2015)... A new program for the "In America" ... of Physical Therapy. , James Earl Jones will ... of physical therapy and discusses how the exercises can ... variety of ailments and injuries. Physical therapists work ... that enhances daily activities such as house cleaning and ...
(Date:5/22/2015)... Portland, Maine (PRWEB) May 22, 2015 ... in single-use swabs for the medical, diagnostic, environmental, ... their entire line of products in the US. ... moving their operations outside the US, Puritan remains ... of products at their Guilford, Maine facility. , ...
(Date:5/22/2015)... Yisrayl Hawkins, Pastor and Overseer at The House of ... on religious leaders to make changes in order to achieve ... blog, discusses the history of war, how it started, why ... says mankind was created to lead peaceful, joyful lives, very ... , “Yahweh created mankind, according to His Plan, which is ...
(Date:5/22/2015)... CA (PRWEB) May 22, 2015 ... lower thirds designed exclusively for Final Cut Pro X. ... with any design. , Intuitive on-screen-controls allow users ... lower third. Reflections, colors, layouts, and much more can ... window. , Pro3rd Impression comes packed ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 World Patent ... products, launches the Troll Motor Guide, a boat patent ... boating. , "The recreational boating industry has reached an ... CEO and Creative Director of World Patent Marketing ... numbers and predicts continued steady growth of seven percent ...
Breaking Medicine News(10 mins):Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 3
... for organically produced food increasing, scientists are reporting new ... do not have higher levels of healthful antioxidants and ... pesticides. Their study appears in ACS, bi-weekly Journal ... study, Pia Knuthsen and colleagues point out that there ...
... Reinberg HealthDay Reporter , TUESDAY, Nov. 2 (HealthDay ... not doing its job of properly monitoring the safety of ... The FDA has the authority to approve both drugs and ... for device approval and safety is lax in both its ...
... Researchers at the Ernest Gallo Clinic and Research Center ... Inc., have determined that two new compounds may be ... the same time. In a paper published ... , the researchers showed that alcohol consumption in rodents ...
... News) -- Anger can be a potent motivator in increasing ... While people generally regard anger as a negative emotion, ... brain that is associated with many positive emotions. And like ... explained the researchers at Utrecht University in the Netherlands. ...
... Patients report decreased pain and improved breathing following ... researchers say the therapy falls short of improving survival. ... Lombardi Comprehensive Cancer Center and presented today at the ... in Vancouver, BC, represents the first of its kind ...
... published in November 3 edition of Journal of ... MPH, MBA, professor of Health Policy and Management at ... for key improvements to primary care in order to ... adults with multiple chronic conditions. Boult and his co-author, ...
Cached Medicine News:Health News: FDA Failing to Monitor Safety of Medical Devices: Report 2Health News: FDA Failing to Monitor Safety of Medical Devices: Report 3Health News: FDA Failing to Monitor Safety of Medical Devices: Report 4Health News:New compounds may treat both alcohol and cigarette addictions 2Health News:Could Anger Make People Want Things More? 2Health News:Lombardi research: Robotic radiosurgery offers palliative care for hilar lung tumors 2Health News:Geriatrician advocates for improvements to primary care to meet the needs of older adults 2Health News:Geriatrician advocates for improvements to primary care to meet the needs of older adults 3
... and CVA for CELL-DYN are assayed linearity ... calibration and to verify patient reportable range ... kits also measure the linear performance of ... kits have customized ranges appropriate for each ...
... is a nucleated red blood cell (nRBC) control ... Coulter LH 750/LH 755 hematology analyzer in its ... for the Coulter LH 750/LH 755. nRBC-Chex for ... cap-pierceable vials. nRBC-Chex for LH has a 75-day ...
... negative whole blood control to test for ... tests and hemoglobin electrophoresis. Sickle-Chex is compatible ... solubility kits. Sickle-Chex is packaged in a ... dispenses an accurate sample volume. No pipeting ...
... Proprietary EX.P.R.T. Release Technology ... No stent shortening,, Unique anatomically designed ... the carotid bifurcation,, 0.014 Rapid Exchange ... profile and flexible atraumatic tip,, Radiopaque ...
Medicine Products: